Innovative coagulation factors: Albumin fusion technology and recombinant single-chain factor VIII

Thrombosis Research

Volumn 131, Issue SUPPL.2, 2013, Pages S2-

  Schulte, Stefan ^a  

^a CSL BEHRING GMBH   (Germany)

Author keywords

Activated factor VII; Albumin fusion; Factor IX; Factor VIII; Half life; Hemophilia A; Hemophilia B

Indexed keywords

ALBUMIN; HYBRID PROTEIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; RECOMBINANT FACTOR IX ALBUMIN FUSION PROTEIN; RECOMBINANT FACTOR VIIA ALBUMIN FUSION PROTEIN; RECOMBINANT VON WILLEBRAND FACTOR; RECOMBINANT VON WILLEBRAND FACTOR ALBUMIN FUSION PROTEIN; UNCLASSIFIED DRUG;

BINDING AFFINITY; CONFERENCE PAPER; DRUG BINDING; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; HEMOPHILIA A; HEMOPHILIA B; HUMAN; IMMUNOGENICITY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; THROMBOPLASTIN TIME;

EID: 84875518350     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/S0049-3848(13)70150-6     Document Type: Conference Paper

References (37)

1. GM Subramanian, M Fiscella, A Lamousé-Smith et al. Albinterferon α-2b: a genetic fusion protein for the treatment of chronic hepatitis C Nat Biotechnol 25 2007 1411 1419 (Pubitemid 350233139)
2. Z Gao, G Bai, J Chen et al. Development, characterization, and evaluation of a fusion protein of a novel glucagon-like peptide-1 (GLP-1) analog and human serum albumin in Pichia pastoris. Biosci Biotechnol Biochem 73 2009 688 694
3. JT Andersen, I Sandlie The versatile MHC class I-related FcRn protects IgG and albumin from degradation: implications for development of new diagnostics and therapeutics Drug Metab Pharmacokinet 24 2009 318 332
4. SR Schmidt Fusion-proteins as biopharmaceuticals-applications and challenges Curr Opin Drug Discov Devel 12 2009 284 295
5. RE Kontermann Strategies to extend plasma half-lives of recombinant antibodies BioDrugs 23 2009 93 109
6. CL Anderson, C Chaudhury, J Kim et al. Perspective-FcRn transports albumin: relevance to immunology and medicine Trends Immunol 27 2006 343 348 (Pubitemid 43963476)
7. H Braley, V Tomasetig, S Zollner et al. Real-time, label-free surface plasmon resonance (Biacore™) analysis of rIX-FP, a recombinant fusion protein linking coagulation factor IX with albumin, shows binding to FcRn comparable to plasma-derived human albumin-correlating with extended half-life in vivo Haemophilia 18 Suppl 3 2012 30 [Abstract PO-TU-019].
8. VT Chuang, U Kragh-Hansen, M Otagiri Pharmaceutical strategies utilizing recombinant human serum albumin Pharm Res 19 2002 569 577 (Pubitemid 34553662)
9. B Elsadek, F Kratz Impact of albumin on drug delivery-New applications on the horizon J Control Release 157 2012 4 28
10. HJ Metzner, T Weimer, S Schulte Half-life extension by fusion to recombinant albumin R Kontermann Therapeutic proteins. Strategies to modulate their plasma half-life 2012 Wiley-VCH Verlag & Co. Weinheim 223 247
11. A Duttaroy, P Kanakaraj, BL Osborn et al. Development of a long-acting insulin analog using albumin fusion technology Diabetes 54 2005 251 258 (Pubitemid 40105120)
12. S Syed, PD Schuyler, M Kulczycky et al. Potent antithrombin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin Blood 89 1997 3243 3252 (Pubitemid 27229809)
13. S Zeuzem, M Sulkowski, E Lawitz et al. Efficacy and safety of albinterferon alfa-2b in combination with ribavirin in treatment-naive, chronic hepatitis C genotype 1 (CHC G1) patients J Hepatol 50 Suppl 1 2009 S378 [Abstract 1041].
14. D Nelson, Y Benhamou, WL Chuang et al. Efficacy and safety results of albinterferon alfa-2b in combination with ribavirin in interferon-alfa treatment naive patients with genotype 2 or 3 chronic hepatitis C J Hepatol 50 Suppl 1 2009 S378 [Abstract 1042].
15. Z Yao, W Dai, J Perry et al. Effect of albumin fusion on the biodistribution of interleukin-2 Cancer Immunol Immunother 53 2004 404 410 (Pubitemid 38657253)
16. RJ Melder, BL Osborn, T Riccobene et al. Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice Cancer Immunol Immunother 54 2005 535 547
17. YJ Huang, PM Lundy, A Lazaris et al. Substantially improved pharmacokinetics of recombinant human butyrylcholinesterase by fusion to human serum albumin BMC Biotechnol 8 2008 50
18. E Erhardtsen Pharmacokinetics of recombinant activated factor VII (rFVIIa) Semin Thromb Hemost 26 2000 385 391
19. S Schulte Use of albumin fusion technology to prolong the half-life of recombinant factor VIIa Thromb Res 122 2008 S14 S19
20. NS Key, LM Aledort, D Beardsley et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors Thromb Haemost 80 1998 912 918 (Pubitemid 28556692)
21. AD Shapiro, GS Gilchrist, WK Hoots et al. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery Thromb Haemost 80 1998 773 778 (Pubitemid 28521721)
22. U Kronthaler, S Schmidbauer, U Liebing et al. Prolonged half-life of recombinant factor VIIa fusion protein-single dose study in rabbits J Thromb Haemost 5 Suppl 2 2009 PP-TH-561
23. S Schulte, T Weimer, W Wormsbächer et al. Prolonged in vivo half-life of FVIIa by fusion to albumin Blood 110 2007 3142
24. T Weimer, W Wormsbächer, U Kronthaler et al. Prolonged in-vivo half-life of factor VIIa by fusion to albumin Thromb Haemost 99 2008 659 667 (Pubitemid 351694221)
25. GC White 2nd, A Beebe, B Nielsen Recombinant factor IX Thromb Haemost 78 1997 261 265 (Pubitemid 27289251)
26. BM Ewenstein, JH Joist, AD Shapiro et al. Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B Transfusion 42 2002 190 197
27. S Björkman, AD Shapiro, E Berntorp Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis Haemophilia 7 2001 133 139 (Pubitemid 32243794)
28. WP Sheffield, A Mamdani, G Hortelano et al. Effects of genetic fusion of factor IX to albumin on in vivo clearance in mice and rabbits Br J Haematol 126 2004 565 573 (Pubitemid 39093100)
29. HJ Metzner, T Weimer, U Kronthaler et al. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX Thromb Haemost 102 2009 634 644
30. S Schulte Half-life extension through albumin fusion technologies Thromb Res 124 2009 S6 S8
31. HJ Metzner, T Weimer, E Raquet et al. Prolonged serum half-life of a recombinant, albumin-fused, human coagulation factor IX (rIX-FP) in different animal species Haemophilia 16 Suppl 4 2010 40 [Abstract 08P41].
32. MW Nolte, TC Nichols, J Mueller-Cohrs et al. Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs J Thromb Haemost 10 2012 1591 1599
33. E Santagostino PROLONG-9FP clinical development program-phase I results of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP) Thromb Res 120 2012 2405 2411
34. E Santagostino, C Negrier, R Klamroth et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients Blood 120 2012 2405 2411
35. U Martinowitz, A Lubetsky Phase I/II, open-label, multicenter, safety, efficacy and PK study of a recombinant coagulation factor IX albumin fusion protein (rIX-FP) in subjects with hemophilia B Thromb Res 131 Suppl 2 2013 S11 S14
36. S Schmidbauer, R Witzel, J Kreuter et al. Physico-chemical characterization of recombinant single chain FVIII Hämostaeseologie 32 2012 A41 [Abstract P2-29].
37. SB Zollner, E Raquet, J Müller-Cohrs et al. Preclinical efficacy and safety of CSL627 novel recombinant, single-chain FVIII Hämostaeseologie 32 2012 A38 [Abstract P2-19].